NYSE - Nasdaq Real Time Price • USD
Danaher Corporation (DHR)
At close: April 24 at 4:00 PM EDT
Pre-Market: 8:40 AM EDT
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
23,737,000.00
23,890,000.00
26,643,000.00
24,802,000.00
22,284,000.00
Cost of Revenue
9,878,000.00
9,856,000.00
10,455,000.00
9,563,000.00
9,809,000.00
Gross Profit
13,859,000.00
14,034,000.00
16,188,000.00
15,239,000.00
12,475,000.00
Operating Expense
8,785,000.00
8,755,000.00
8,652,000.00
8,852,000.00
8,244,000.00
Operating Income
5,074,000.00
5,279,000.00
7,536,000.00
6,387,000.00
4,231,000.00
Net Non Operating Interest Income Expense
30,000.00
17,000.00
-163,000.00
-220,000.00
-204,000.00
Other Income Expense
-312,000.00
-252,000.00
-227,000.00
344,000.00
468,000.00
Pretax Income
4,792,000.00
5,044,000.00
7,146,000.00
6,511,000.00
4,495,000.00
Tax Provision
723,000.00
823,000.00
818,000.00
1,064,000.00
849,000.00
Net Income Common Stockholders
4,402,000.00
4,743,000.00
7,103,000.00
6,269,000.00
3,510,000.00
Average Dilution Earnings
--
--
--
--
1,000.00
Diluted NI Available to Com Stockholders
4,402,000.00
4,743,000.00
7,103,000.00
6,269,000.00
3,510,000.00
Basic EPS
5.95
6.44
9.80
8.77
4.97
Diluted EPS
5.89
6.38
9.66
8.61
4.89
Basic Average Shares
739,300.00
736,500.00
725,100.00
714,600.00
706,200.00
Diluted Average Shares
745,950.00
743,100.00
737,100.00
736,800.00
718,700.00
Total Operating Income as Reported
4,997,000.00
5,202,000.00
7,536,000.00
6,377,000.00
4,231,000.00
Total Expenses
18,663,000.00
18,611,000.00
19,107,000.00
18,415,000.00
18,053,000.00
Net Income from Continuing & Discontinued Operation
4,402,000.00
4,764,000.00
7,209,000.00
6,433,000.00
3,646,000.00
Normalized Income
4,339,021.29
4,437,783.00
6,568,106.00
5,195,900.00
3,283,483.00
Interest Income
315,000.00
303,000.00
41,000.00
11,000.00
71,000.00
Interest Expense
285,000.00
286,000.00
204,000.00
231,000.00
275,000.00
Net Interest Income
30,000.00
17,000.00
-163,000.00
-220,000.00
-204,000.00
EBIT
5,077,000.00
5,330,000.00
7,350,000.00
6,742,000.00
4,770,000.00
EBITDA
7,294,000.00
7,496,000.00
9,482,000.00
8,804,000.00
6,545,000.00
Reconciled Cost of Revenue
9,878,000.00
9,856,000.00
10,455,000.00
9,563,000.00
9,809,000.00
Reconciled Depreciation
2,217,000.00
2,166,000.00
2,132,000.00
2,062,000.00
1,775,000.00
Net Income from Continuing Operation Net Minority Interest
4,069,000.00
4,221,000.00
6,328,000.00
5,447,000.00
3,646,000.00
Total Unusual Items Excluding Goodwill
-318,000.00
-259,000.00
-271,000.00
300,000.00
447,000.00
Total Unusual Items
-318,000.00
-259,000.00
-271,000.00
300,000.00
447,000.00
Normalized EBITDA
7,612,000.00
7,755,000.00
9,753,000.00
8,504,000.00
6,098,000.00
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
Tax Effect of Unusual Items
-47,978.71
-42,217.00
-30,894.00
48,900.00
84,483.00
12/31/2020 - 12/29/1978
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
TMO Thermo Fisher Scientific Inc.
577.39
+0.49%
MEDP Medpace Holdings, Inc.
397.56
-2.36%
DGX Quest Diagnostics Incorporated
137.55
+0.62%
ILMN Illumina, Inc.
122.87
-1.28%
IDXX IDEXX Laboratories, Inc.
494.26
+0.09%
ME 23andMe Holding Co.
0.4671
-5.39%
A Agilent Technologies, Inc.
137.49
-1.23%
WAT Waters Corporation
310.25
-0.97%
GH Guardant Health, Inc.
18.10
+4.38%
EXAS Exact Sciences Corporation
63.24
-0.46%